BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34687595)

  • 1. Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients.
    Klotz DM; Link T; Goeckenjan M; Wimberger P; Poetsch AR; Jaschke N; Hofbauer LC; Göbel A; Rachner TD; Kuhlmann JD
    Clin Chem Lab Med; 2022 Jan; 60(1):109-117. PubMed ID: 34687595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker.
    Klotz DM; Link T; Goeckenjan M; Wimberger P; Kuhlmann JD
    Mol Oncol; 2021 Sep; 15(9):2491-2503. PubMed ID: 33690968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis.
    Klotz DM; Kuhlmann JD; Link T; Goeckenjan M; Hofbauer LC; Göbel A; Rachner TD; Wimberger P
    Front Oncol; 2022; 12():974885. PubMed ID: 36338759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
    Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
    Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.
    Link T; Passek S; Wimberger P; Frank K; Vassileva YD; Kramer M; Kuhlmann JD
    Int J Cancer; 2020 May; 146(9):2608-2618. PubMed ID: 31509615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.
    Klotz DM; Link T; Wimberger P; Kuhlmann JD
    Mol Oncol; 2021 Dec; 15(12):3626-3638. PubMed ID: 33738970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma.
    Saygili U; Guclu S; Uslu T; Erten O; Dogan E
    Int J Gynecol Cancer; 2002; 12(5):438-42. PubMed ID: 12366659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
    Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of serum human epididymis protein 4 in epithelial ovarian cancer and its correlation with prognosis].
    Zheng H; Gao YN; Gao WJ; Gao M; Yan X
    Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):445-9. PubMed ID: 24119905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway.
    Huo Q; Xu C; Shao Y; Yu Q; Huang L; Liu Y; Bao H
    Int J Biol Sci; 2021; 17(2):574-588. PubMed ID: 33613114
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    Bendifallah S; Body G; Daraï E; Ouldamer L
    Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
    Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
    Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.
    Leung F; Dimitromanolakis A; Kobayashi H; Diamandis EP; Kulasingam V
    Clin Biochem; 2013 Oct; 46(15):1462-8. PubMed ID: 23528302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125.
    Jin C; Yang M; Han X; Chu H; Zhang Y; Lu M; Wang Z; Xu X; Liu W; Wang F; Ju S
    J Ovarian Res; 2019 Nov; 12(1):114. PubMed ID: 31767040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
    Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
    Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer.
    Yamada Y; Kawaguchi R; Iwai K; Niiro E; Morioka S; Tanase Y; Kobayashi H
    J Obstet Gynaecol; 2020 Jan; 40(1):102-106. PubMed ID: 31335252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.